Processa Pharmaceuticals (PCSA) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
13 Nov, 2026Executive summary
July acquisition of Vidya added VT-7208, a BTK inhibitor targeting food allergy, CSU and relapsing MS; $200.0M gross private placement accompanied the transaction.
Q3 net loss was $183.2M, driven mainly by a $178.0M acquired in-process R&D charge with no alternative future use.
Financial highlights
Q3 2026 R&D was $1.8M vs. $1.7M YoY; G&A was $4.3M vs. $1.8M; operating loss was $184.1M vs. $3.5M.
9M 2026 net loss was $189.8M vs. $10.2M YoY; operating loss was $189.8M vs. $10.3M, including $178.0M acquired IPR&D expense.
Q3 basic and diluted loss per share was $61.58 vs. $1.81; 9M loss per share was $68.18 vs. $10.48.
No product revenue; 9M operating cash use was $10.8M vs. $8.5M, while cash and equivalents reached $180.2M at September 30.
Outlook and guidance
Net proceeds of $187.1M from the private placement are intended to fund operations into H2 2029 and through VT-7208 Phase 2 proof-of-concept milestones.
Food allergy Phase 2 initiation targeted H2 2026, with PoC data H2 2027; CSU initiation H2 2026 and data H1 2028; relapsing MS initiation H1 2027 and data H2 2028.
Clinical trial costs were expected to rise in H2 2026 as three VT-7208 Phase 2 trials advance; operating cash flows are expected to remain negative for the foreseeable future.
Management expects cash to fund planned operations for at least 12 months, but substantial doubt about going concern remains due to conditional preferred-stock conversion and potential cash settlement.
Latest events from Processa Pharmaceuticals
- VT7208 advances toward Phase 2 as an oral FcRn program targets a first-in-class opportunity.PCSA
Company presentation - Vidya deal funds three planned Phase 2 programs into H2 2029, pending key votes.PCSA
Proxy filing - VT-7208’s Phase 2 strategy is funded into 2H 2029, pending key shareholder votes.PCSA
Proxy filing - A reverse split vote is a key step toward Nasdaq listing and a later preferred-conversion vote.PCSA
Proxy filing - Merger and $200 million PIPE set up major conversion dilution and five critical stockholder votes.PCSA
Proxy filing - Reverse split approval is pivotal to Nasdaq listing and preferred-share conversion.PCSA
Proxy filing - A 306.6 million-share resale registration accompanies the shift to VT-7208-led development.PCSA
Registration filing - Merger and $200M PIPE fund VT-7208, a promising BTK inhibitor, into Phase 2 trials.PCSA
Company presentation - Parallel phase II trials for a novel BTK inhibitor are funded through 2029, with key data in 2027–2028.PCSA
H.C. Wainwright 28th Annual Global Investment Conference